This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up
Menü
Schließen
Maternal ImmunisationMaternalMaternal Immunisation HomepageSafety ProfileDosingOlder AdultsOlder AdultsOlder Adults HomepageSafety ProfileDosingUseful ResourcesUseful ResourcesVideosMaterialsPreparationPrescribing Information


This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 of the SmPC for how to report adverse reactions.

Please refer to the ABRYSVO Summary of Product Characteristics for 
full prescribing information 

Most local and systemic reactions in maternal participants were mild to moderate in severity and resolved within 2-3 days of onset.1


In pregnant women at 24-36 weeks of gestation, the most frequently reported adverse reactions were vaccination site pain (41%), headache (31%), and myalgia (27%).1



Tabulated Adverse Events (AE) in pregnant women

Please refer to the SmPC for additional safety information.

 

Scroll left to view table
System organ class
Very Common
(1/10)
Common
(
1/100 to <1/10)
Immune system disorders  - -
Nervous system disorders Headache -
Musculoskeletal and connective
tissue disorders
Myalgia -
General disorders and administration
site conditions
Vaccination site pain Vaccination site redness,
Vaccination site swelling



No safety signals were detected in infants up to 24 months of age.1


The incidences of adverse events reported within 1 month after birth in infants were similar in the ABRYSVO group (37%) and the placebo group (35%). Major birth outcomes assessed in the ABRYSVO group compared to placebo included premature birth (201 (6%) and 169 (5%), respectively), low birth weight (181 (5%) and 155 (4%), respectively) and congenital anomalies (174 (5%) and 203 (6%), respectively). 1

In a phase 3 study (Study 1), maternal adverse events reported within 1 month after vaccination were similar in the ABRYSVO group (14%) and the placebo group (13%). 1

Contraindications1

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 of the SmPC.

Special warnings and precautions for use1

Traceability

In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.

Hypersensitivity and anaphylaxis

Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.

Anxiety-related reactions

Anxiety-related reactions, including vasovagal reactions (syncope), hyperventilation or stress-related reactions may occur in association with vaccination as a psychogenic response to the needle injection. It is important that procedures are in place to avoid injury from fainting.

Concurrent illness

Vaccination should be postponed in individuals suffering from an acute febrile illness. However, the presence of a minor infection, such as a cold, should not result in the deferral of vaccination.

Thrombocytopenia and coagulation disorders

ABRYSVO should be given with caution to individuals with thrombocytopenia or any coagulation disorder since bleeding or bruising may occur following an intramuscular administration to these individuals.

Immunocompromised individuals

The efficacy and safety of the vaccine have not been assessed in immunocompromised individuals, including those receiving immunosuppressant therapy. The efficacy of ABRYSVO may be lower in immunosuppressed individuals.

Individuals less than 24 weeks of gestation

ABRYSVO has not been studied in pregnant individuals less than 24 weeks of gestation. Since protection of the infant against RSV depends on transfer of maternal antibodies across the placenta, ABRYSVO should be administered between weeks 24 and 36 of gestation (see sections 4.2 and 5.1 of the ABRYSVO SmPC for further information) 

Limitations of vaccine effectiveness

As with any vaccine, a protective immune response may not be elicited after vaccination 

Excipient

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium-free’. 

ABRYSVO - Maternal Immunisation

Learn more about maternal immunisation with ABRYSVO.

Learn moreLoading
Dosing - Pregnant Women

Find out more about the dosing information of ABRYSVO for maternal patients.

Learn moreLoading
Preparation of ABRYSVO

Watch a video on how to prepare ABRYSVO for administration. 

Click hereLoading

Reference:

  1. ABRYSVO Summary of Product Characteristics.

Legal Category: S1A
Further information is available upon request

PP-A1G-IRL-0052 Date of Preparation: September 2024

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No